Cenicriviroc

05/20

ALTERNATE NAMES: TAK-652; TBR-652; (5E)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-N-[4-[(S)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2H-1-benzazocine-5-carboxamide; (S,E)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide

CATALOG #:
B3026-1 1 mg
B3026-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{41}H_{52}N_4O_4S$

MOLECULAR WEIGHT: 696.94

CAS NUMBER: 497223-25-3

APPEARANCE: Yellow Solid

PURITY: ≥98%

SOLUBILITY:
~20 mg/ml in DMSO and DMF
~5 mg/ml in ethanol

DESCRIPTION: Cenicriviroc is a potent inhibitor of C-C chemokine receptors CCR5 and CCR2. It is an orally bioavailable derivative of TAK-779 with potent anti-HIV-1 activity. It blocks the binding of MIP-1α and MIP-1β to CCR5 with an IC_{50} of 2.3 nM. It inhibits the binding of MCP-1 to CCR2b with an IC_{50} of 5.9 nM. It inhibits the replication of R5X4HIV-1 in U87.CD4.CCR5 cells at a concentration of 100 nM. It shows potent anti-inflammatory and antifibrotic activity in animal models of fibrosis.

STORAGE TEMPERATURE: -20ºC. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Lefebvre, E., Moyle, G., Reshef, R., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 11(6):e0158156, (2016).
2. Baba, M., Takashima, K., Miyake, H., et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49(11), 4584-4591 (2005).

RELATED PRODUCTS:

Acyclovir (Cat. No. 2200)
Valganciclovir Hydrochloride (Cat. No. B2708)
Emtricitabine (Cat. No. B2678)
Cabotegravir (Cat. No. B2535)
Ganciclovir (Cat. No. 1918)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***